Shuo Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Shuo Xu has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
Jianhang Zhang
3 shared publicationsXiaxin Yang
Department of Neurology, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China
3 shared publicationsChuanxin Wang
Department of Clinical Laboratory, The Second Cheeloo Hospital of Shandong University, Jinan, China
2 shared publications- Chuanxin Wang
Department of Clinical Laboratory, The Second Hospital of Shandong University, Jinan, China
2 shared publications Feng Tian
Department of Clinical Laboratory, The Second Cheeloo Hospital of Shandong University, Jinan, China
2 shared publicationsJuan Li
2 shared publications
Latest Publications
- Open Access
- 29 August 2026
- Published by Springer Nature in Oncogenesis
- Vol. 15 (1)
Stanniocalcin 1 contributes to glioma stem cells phenotypic plasticity through NOTCH1/STAT3/GFPT2 axis
Glioma stem cells (GSCs) are key drivers of glioblastoma (GBM) tumorigenesis, invasion, therapy resistance, and recurrence and exhibit remarkable phenotypic plasticity. Stanniocalcin 1 (STC1) has been implicated in tumor progression and cancer stemness; however, its role and the molecular mechanisms through which it shapes GSC plasticity and malignant traits remain poorly understood. Here, transcriptomic RNA sequencing identified STC1 as a malignancy-associated gene enriched in GBM and mesenchymal (MES)-like GSCs. Comprehensive bioinformatic analyses further validated that STC1 was highly expressed in MES-like GBM/GSCs and closely associated with poor patient survival. Functional studies revealed that STC1 promoted multiple malignant properties of GSCs, including self-renewal, migration, invasion, tumorigenicity, and cellular plasticity. Conversely, STC1 silencing attenuated these effects. Mechanistically, STC1 activated the NOTCH1/STAT3 signaling cascade, leading to transcriptional upregulation of GFPT2, a key rate-limiting enzyme of the hexosamine biosynthetic pathway. This subsequently enhanced global O-GlcNAcylation, including modification of P65, thereby facilitating GSC plasticity and malignant progression. Genetic and pharmacological interventions targeting this signaling axis effectively mitigated the oncogenic effects driven by STC1. In conclusion, our study reveals that STC1 is a key regulator of GSC phenotypic plasticity and aggressiveness through the NOTCH1/STAT3/GFPT2/O-GlcNAcylation pathway. These results provide new mechanistic insights into GBM progression and suggest that targeting STC1-associated signaling networks may represent a potential therapeutic strategy for GBM.
- 29 August 2026
- Published by Springer Nature in Oncogenesis
- Vol. 15 (1)
Open AccessStanniocalcin 1 contributes to glioma stem cells phenotypic plasticity through NOTCH1/STAT3/GFPT2 axis
Glioma stem cells (GSCs) are key drivers of glioblastoma (GBM) tumorigenesis, invasion, therapy resistance, and recurrence and exhibit remarkable phenotypic plasticity. Stanniocalcin 1 (STC1) has been implicated in tumor progression and cancer stemness; however, its role and the molecular mechanisms through which it shapes GSC plasticity and malignant traits remain poorly understood. Here, transcriptomic RNA sequencing identified STC1 as a malignancy-associated gene enriched in GBM and mesenchymal (MES)-like GSCs. Comprehensive bioinformatic analyses further validated that STC1 was highly expressed in MES-like GBM/GSCs and closely associated with poor patient survival. Functional studies revealed that STC1 promoted multiple malignant properties of GSCs, including self-renewal, migration, invasion, tumorigenicity, and cellular plasticity. Conversely, STC1 silencing attenuated these effects. Mechanistically, STC1 activated the NOTCH1/STAT3 signaling cascade, leading to transcriptional upregulation of GFPT2, a key rate-limiting enzyme of the hexosamine biosynthetic pathway. This subsequently enhanced global O-GlcNAcylation, including modification of P65, thereby facilitating GSC plasticity and malignant progression. Genetic and pharmacological interventions targeting this signaling axis effectively mitigated the oncogenic effects driven by STC1. In conclusion, our study reveals that STC1 is a key regulator of GSC phenotypic plasticity and aggressiveness through the NOTCH1/STAT3/GFPT2/O-GlcNAcylation pathway. These results provide new mechanistic insights into GBM progression and suggest that targeting STC1-associated signaling networks may represent a potential therapeutic strategy for GBM.
- Open Access
- 10 June 2026
- Published by Elsevier in SSRN Electronic Journal
Noninvasive Detection, Classification, and Prognosis Prediction of Glioma Using Peripheral Blood Mononuclear Cell DNA Methylation
Background: Accurate diagnosis and risk stratification of adult-type diffuse gliomas remain hampered by limited neuroimaging specificity, invasive tissue biopsy, and low sensitivity of conventional liquid biopsies. Peripheral blood mononuclear cells (PBMCs) reflect tumor-induced systemic immune remodeling, representing a promising reservoir of epigenetic biomarkers.Methods: We profiled PBMC methylation from 559 individuals, including 152 gliomas, 15 brain metastases (BM), 33 primary central nervous system lymphomas (PCNSL), 194 extracranial tumors (ETs), and 165 healthy controls (HCs) using the Infinium MethylationEPIC BeadChip (935K). Machine learning models were built and validated via 8:2 stratified sampling with 50 iterations for glioma detection, differential diagnosis, subtyping, and grading. Univariate and multivariate Cox regression were applied to predict glioblastoma (GBM) prognosis.Findings: Glioma patients exhibited a predominant global hypomethylation pattern in PBMCs, with alterations enriched in T cell subsets. The model distinguishing gliomas from HCs/ETs achieved a median AUROC of 0.983. For differentiating gliomas from BM/PCNSL, the median AUROC was 0.959. Subtyping (GBM vs. oligodendroglioma [OD]/astrocytoma [AS]) reached a median AUROC of 0.923, and grade 4 vs. lower-grade yielded 0.855. Prognostic risk scores for progression-free survival (PFS) and overall survival (OS) in GBM remained independent prognostic factors after adjustment for TERT promoter mutation and MGMT promoter methylation (PFS: HR = 1.46, 95% CI: 1.30–1.63; OS: HR = 1.34, 95% CI: 1.13–1.60).Interpretation: This study defines a comprehensive PBMC methylation landscape of gliomas, identifying a subtype-specific systemic hypomethylation signature. Our epigenetic liquid biopsy enables noninvasive detection, classification, and prognostic stratification for gliomas.
- 10 June 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessNoninvasive Detection, Classification, and Prognosis Prediction of Glioma Using Peripheral Blood Mononuclear Cell DNA Methylation
Background: Accurate diagnosis and risk stratification of adult-type diffuse gliomas remain hampered by limited neuroimaging specificity, invasive tissue biopsy, and low sensitivity of conventional liquid biopsies. Peripheral blood mononuclear cells (PBMCs) reflect tumor-induced systemic immune remodeling, representing a promising reservoir of epigenetic biomarkers.Methods: We profiled PBMC methylation from 559 individuals, including 152 gliomas, 15 brain metastases (BM), 33 primary central nervous system lymphomas (PCNSL), 194 extracranial tumors (ETs), and 165 healthy controls (HCs) using the Infinium MethylationEPIC BeadChip (935K). Machine learning models were built and validated via 8:2 stratified sampling with 50 iterations for glioma detection, differential diagnosis, subtyping, and grading. Univariate and multivariate Cox regression were applied to predict glioblastoma (GBM) prognosis.Findings: Glioma patients exhibited a predominant global hypomethylation pattern in PBMCs, with alterations enriched in T cell subsets. The model distinguishing gliomas from HCs/ETs achieved a median AUROC of 0.983. For differentiating gliomas from BM/PCNSL, the median AUROC was 0.959. Subtyping (GBM vs. oligodendroglioma [OD]/astrocytoma [AS]) reached a median AUROC of 0.923, and grade 4 vs. lower-grade yielded 0.855. Prognostic risk scores for progression-free survival (PFS) and overall survival (OS) in GBM remained independent prognostic factors after adjustment for TERT promoter mutation and MGMT promoter methylation (PFS: HR = 1.46, 95% CI: 1.30–1.63; OS: HR = 1.34, 95% CI: 1.13–1.60).Interpretation: This study defines a comprehensive PBMC methylation landscape of gliomas, identifying a subtype-specific systemic hypomethylation signature. Our epigenetic liquid biopsy enables noninvasive detection, classification, and prognostic stratification for gliomas.
- Top Cited PapersOpen Access
- 27 June 2025
- Published by JMIR Publications Inc. in JMIR Medical Informatics
- Vol. 13, e69485
Performance of Large Language Models in the Non-English Context: Qualitative Study of Models Trained on Different Languages in Chinese Medical Examinations
Background: Research on large language models (LLMs) in the medical field has predominantly focused on models trained with English-language corpora, evaluating their performance within English-speaking contexts. The performances of models trained with non–English language corpora and their performance in non-English contexts remain underexplored. Objective: This study aimed to evaluate the performances of LLMs trained on different languages corpora by using the Chinese National Medical Licensing Examination (CNMLE) as a benchmark and constructed analogous questions. Methods: Under different prompt settings, we sequentially posed questions to 7 LLMs: 2 primarily trained on English-language corpora and 5 primarily on Chinese-language corpora. The models’ responses were compared against standard answers to calculate the accuracy rate of each model. Further subgroup analyses were conducted by categorizing the questions based on various criteria. We also collected error sets to explore patterns of mistakes across different models. Results: Under the zero-shot setting, 6 out of 7 models exceeded the passing level, with the highest accuracy rate achieved by the Chinese LLM Baichuan (86.67%), followed by ChatGPT (83.83%). In the constructed questions, all 7 models exceeded the passing threshold, with Baichuan maintaining the highest accuracy rate (87.00%). In few-shot learning, all models exceeded the passing threshold. Baichuan, ChatGLM, and ChatGPT retained the highest accuracy. While Llama showed marked improvement over previous tests, the relative performance rankings of other models stayed similar to previous results. In subgroup analyses, English models demonstrated comparable or superior performance to Chinese models on questions related to ethics and policy. All models except Llama generally had higher accuracy rates for simple questions than for complex ones. The error set of ChatGPT was similar to those of other Chinese models. Multimodel cross-verification outperformed single model, particularly improving accuracy rate on simple questions. The implementation of dual-model and tri-model verification achieved accuracy rates of 94.17% and 96.33% respectively. Conclusions: At the current level, LLMs trained primarily on English corpora and those trained mainly on Chinese corpora perform similarly well in CNMLE, with Chinese models still outperforming. The performance difference between ChatGPT and other Chinese LLMs are not solely due to communication barriers but are more likely influenced by disparities in the training data. By using a method of cross-verification with multiple LLMs, excellent performance can be achieved in medical examinations.
- 27 June 2025
- Published by JMIR Publications Inc. in JMIR Medical Informatics
- Vol. 13, e69485
Top Cited PapersOpen AccessPerformance of Large Language Models in the Non-English Context: Qualitative Study of Models Trained on Different Languages in Chinese Medical Examinations
Background: Research on large language models (LLMs) in the medical field has predominantly focused on models trained with English-language corpora, evaluating their performance within English-speaking contexts. The performances of models trained with non–English language corpora and their performance in non-English contexts remain underexplored. Objective: This study aimed to evaluate the performances of LLMs trained on different languages corpora by using the Chinese National Medical Licensing Examination (CNMLE) as a benchmark and constructed analogous questions. Methods: Under different prompt settings, we sequentially posed questions to 7 LLMs: 2 primarily trained on English-language corpora and 5 primarily on Chinese-language corpora. The models’ responses were compared against standard answers to calculate the accuracy rate of each model. Further subgroup analyses were conducted by categorizing the questions based on various criteria. We also collected error sets to explore patterns of mistakes across different models. Results: Under the zero-shot setting, 6 out of 7 models exceeded the passing level, with the highest accuracy rate achieved by the Chinese LLM Baichuan (86.67%), followed by ChatGPT (83.83%). In the constructed questions, all 7 models exceeded the passing threshold, with Baichuan maintaining the highest accuracy rate (87.00%). In few-shot learning, all models exceeded the passing threshold. Baichuan, ChatGLM, and ChatGPT retained the highest accuracy. While Llama showed marked improvement over previous tests, the relative performance rankings of other models stayed similar to previous results. In subgroup analyses, English models demonstrated comparable or superior performance to Chinese models on questions related to ethics and policy. All models except Llama generally had higher accuracy rates for simple questions than for complex ones. The error set of ChatGPT was similar to those of other Chinese models. Multimodel cross-verification outperformed single model, particularly improving accuracy rate on simple questions. The implementation of dual-model and tri-model verification achieved accuracy rates of 94.17% and 96.33% respectively. Conclusions: At the current level, LLMs trained primarily on English corpora and those trained mainly on Chinese corpora perform similarly well in CNMLE, with Chinese models still outperforming. The performance difference between ChatGPT and other Chinese LLMs are not solely due to communication barriers but are more likely influenced by disparities in the training data. By using a method of cross-verification with multiple LLMs, excellent performance can be achieved in medical examinations.
- Open Access
- 26 June 2025
- Published by Elsevier in Neurotherapeutics
- Vol. 22 (5) , e00630
Identification of plasma SEMA3E as the diagnostic biomarker for human epilepsy based on integrated bioinformatics analysis
- 26 June 2025
- Published by Elsevier in Neurotherapeutics
- Vol. 22 (5) , e00630
Open AccessIdentification of plasma SEMA3E as the diagnostic biomarker for human epilepsy based on integrated bioinformatics analysis
- Open Access
- 9 May 2025
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 16, 1564735
Long-term outcome of vagus nerve stimulation therapy in drug-resistant epilepsy: a retrospective single-center study
Introduction: Vagus nerve stimulation (VNS) has garnered widespread application in patients with drug-resistant epilepsy (DRE), while the efficacy and prognostic factors of VNS in DRE remain elusive. Moreover, clinical determinants associated with rapid response to VNS have never been uncovered. This study aimed to elucidate factors influencing efficacy and rapid response to VNS.Methods: A consecutive series of patients with DRE undergoing VNS surgery from January 2014 to December 2023 was collected to describe VNS efficacy. Both univariate and multivariate analyses were performed to identify statistically significant prognostic factors, and a predictive model was developed. Furthermore, we examined clinical determinants of rapid/slow response to VNS and VNS current changes.Results: A total of 65 patients underwent VNS implantation. Seizure frequency significantly decreased post-VNS, with mean seizure reduction rates of 35.7, 49.0, 48.5, 52.8, 63.2, and 66.8% at 6 (n = 65), 12 (n = 65), 24 (n = 50), 36 (n = 40), 60 (n = 31), and 84 (n = 19) months, respectively. At final follow-up, 61.5% (40/65) were responders (50–100% seizure reduction), and 10.8% (7/65) achieved seizure freedom for ≥1 year. Univariate analysis identified age at seizure onset ≥6 years (p = 0.003), baseline seizure frequency ≤30/month (p = 0.001), focal seizures (p = 0.002), developmental and epileptic encephalopathies (p = 0.037), and surgical history (p < 0.001) as significant prognostic factors. Multivariate analysis confirmed age at seizure onset ≥6 years (OR: 5.726, p = 0.039), baseline seizure frequency ≤30/month (OR: 4.697, p = 0.048), and focal seizures (OR: 4.791, p = 0.025) as independent predictors, enabling the development of a predictive model for VNS efficacy. Additionally, among responders, the median response duration was 6 months (range: 1–60 months), with baseline seizure frequency ≤30/month significantly associated with rapid response of VNS in DRE (p = 0.033).Conclusion: Vagus nerve stimulation is effective for treating DRE, with efficacy increasing with follow-up duration. Age at seizure onset ≥6 years, baseline seizure frequency ≤30/month, and focal seizure were predictive of VNS success, underscoring the need for careful preoperative assessment of patients with DRE before VNS surgery.
- 9 May 2025
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 16, 1564735
Open AccessLong-term outcome of vagus nerve stimulation therapy in drug-resistant epilepsy: a retrospective single-center study
Introduction: Vagus nerve stimulation (VNS) has garnered widespread application in patients with drug-resistant epilepsy (DRE), while the efficacy and prognostic factors of VNS in DRE remain elusive. Moreover, clinical determinants associated with rapid response to VNS have never been uncovered. This study aimed to elucidate factors influencing efficacy and rapid response to VNS.Methods: A consecutive series of patients with DRE undergoing VNS surgery from January 2014 to December 2023 was collected to describe VNS efficacy. Both univariate and multivariate analyses were performed to identify statistically significant prognostic factors, and a predictive model was developed. Furthermore, we examined clinical determinants of rapid/slow response to VNS and VNS current changes.Results: A total of 65 patients underwent VNS implantation. Seizure frequency significantly decreased post-VNS, with mean seizure reduction rates of 35.7, 49.0, 48.5, 52.8, 63.2, and 66.8% at 6 (n = 65), 12 (n = 65), 24 (n = 50), 36 (n = 40), 60 (n = 31), and 84 (n = 19) months, respectively. At final follow-up, 61.5% (40/65) were responders (50–100% seizure reduction), and 10.8% (7/65) achieved seizure freedom for ≥1 year. Univariate analysis identified age at seizure onset ≥6 years (p = 0.003), baseline seizure frequency ≤30/month (p = 0.001), focal seizures (p = 0.002), developmental and epileptic encephalopathies (p = 0.037), and surgical history (p < 0.001) as significant prognostic factors. Multivariate analysis confirmed age at seizure onset ≥6 years (OR: 5.726, p = 0.039), baseline seizure frequency ≤30/month (OR: 4.697, p = 0.048), and focal seizures (OR: 4.791, p = 0.025) as independent predictors, enabling the development of a predictive model for VNS efficacy. Additionally, among responders, the median response duration was 6 months (range: 1–60 months), with baseline seizure frequency ≤30/month significantly associated with rapid response of VNS in DRE (p = 0.033).Conclusion: Vagus nerve stimulation is effective for treating DRE, with efficacy increasing with follow-up duration. Age at seizure onset ≥6 years, baseline seizure frequency ≤30/month, and focal seizure were predictive of VNS success, underscoring the need for careful preoperative assessment of patients with DRE before VNS surgery.
- Open Access
- 11 December 2024
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 30 (12) , e70128
CCN1 Promotes Mesenchymal Phenotype Transition Through Activating NF‐κB Signaling Pathway Regulated by S100A8 in Glioma Stem Cells
Background: The presence of glioma stem cells (GSCs) and the occurrence of mesenchymal phenotype transition contribute to the miserable prognosis of glioblastoma (GBM). Cellular communication network factor 1 (CCN1) is upregulated within various malignancies and associated with cancer development and progression, while the implications of CCN1 in the phenotype transition and tumorigenicity of GSCs remain unclear.Methods: Data for bioinformatic analysis were obtained from The Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA) databases. A range of primary GBM and GSC cell models were then used to demonstrate the regulatory role of CCN1 via the phenotype validation, tumor sphere formation assays, extreme limiting dilution assays (ELDA), and transwell assays. To screen out the downstream signaling pathway, we employed high‐throughput RNA‐seq. Intracranial xenograft GSC mouse models were used to investigate the role of CCN1 in vivo.Results: Among the CCN family members, CCN1 was highly expressed in MES‐GBM/GSCs and was correlated with a poor prognosis. Both in vitro and in vivo assays indicated that knockdown of CCN1 in MES‐GSCs reduced the tumor stemness, proliferation, invasion, and tumorigenicity, whereas CCN1 overexpression in PN‐GSCs exhibited the opposite effects. Mechanistically, CCN1 triggered the FAK/STAT3 signaling in autocrine and paracrine manners to upregulate the expression of S100A8. Knockdown of S100A8 inactivated NF‐κB/p65 pathway and significantly suppressed the tumorigenesis of MES‐GSCs.Conclusion: Our findings reveal that CCN1 may be an important factor in the enhanced invasiveness and MES phenotype transition of GSCs and highlight the potential to target CCN1 for treating GBM.
- 11 December 2024
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 30 (12) , e70128
Open AccessCCN1 Promotes Mesenchymal Phenotype Transition Through Activating NF‐κB Signaling Pathway Regulated by S100A8 in Glioma Stem Cells
Background: The presence of glioma stem cells (GSCs) and the occurrence of mesenchymal phenotype transition contribute to the miserable prognosis of glioblastoma (GBM). Cellular communication network factor 1 (CCN1) is upregulated within various malignancies and associated with cancer development and progression, while the implications of CCN1 in the phenotype transition and tumorigenicity of GSCs remain unclear.Methods: Data for bioinformatic analysis were obtained from The Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA) databases. A range of primary GBM and GSC cell models were then used to demonstrate the regulatory role of CCN1 via the phenotype validation, tumor sphere formation assays, extreme limiting dilution assays (ELDA), and transwell assays. To screen out the downstream signaling pathway, we employed high‐throughput RNA‐seq. Intracranial xenograft GSC mouse models were used to investigate the role of CCN1 in vivo.Results: Among the CCN family members, CCN1 was highly expressed in MES‐GBM/GSCs and was correlated with a poor prognosis. Both in vitro and in vivo assays indicated that knockdown of CCN1 in MES‐GSCs reduced the tumor stemness, proliferation, invasion, and tumorigenicity, whereas CCN1 overexpression in PN‐GSCs exhibited the opposite effects. Mechanistically, CCN1 triggered the FAK/STAT3 signaling in autocrine and paracrine manners to upregulate the expression of S100A8. Knockdown of S100A8 inactivated NF‐κB/p65 pathway and significantly suppressed the tumorigenesis of MES‐GSCs.Conclusion: Our findings reveal that CCN1 may be an important factor in the enhanced invasiveness and MES phenotype transition of GSCs and highlight the potential to target CCN1 for treating GBM.
- Open Access
- 7 September 2024
- Published by Elsevier in Neurotherapeutics
- Vol. 21 (6) , e00447
Mitochondria-related HSDL2 is a potential biomarker in temporal lobe epilepsy by modulating astrocytic lipid metabolism
- 7 September 2024
- Published by Elsevier in Neurotherapeutics
- Vol. 21 (6) , e00447
Open AccessMitochondria-related HSDL2 is a potential biomarker in temporal lobe epilepsy by modulating astrocytic lipid metabolism
- Open Access
- 28 June 2023
- Published by Springer Nature in British Journal of Cancer
- Vol. 129 (3) , 426-443
Chromatin accessibility uncovers KRAS-driven FOSL2 promoting pancreatic ductal adenocarcinoma progression through up-regulation of CCL28
Background: The epigenetic mechanisms involved in the progression of pancreatic ductal adenocarcinoma (PDAC) remain largely unexplored. This study aimed to identify key transcription factors (TFs) through multiomics sequencing to investigate the molecular mechanisms of TFs that play critical roles in PDAC. Methods: To characterise the epigenetic landscape of genetically engineered mouse models (GEMMs) of PDAC with or without KRAS and/or TP53 mutations, we employed ATAC-seq, H3K27ac ChIP-seq, and RNA-seq. The effect of Fos-like antigen 2 (FOSL2) on survival was assessed using the Kaplan–Meier method and multivariate Cox regression analysis for PDAC patients. To study the potential targets of FOSL2, we performed Cleavage Under Targets and Tagmentation (CUT&Tag). To explore the functions and underlying mechanisms of FOSL2 in PDAC progression, we employed several assays, including CCK8, transwell migration and invasion, RT-qPCR, Western blotting analysis, IHC, ChIP-qPCR, dual-luciferase reporter, and xenograft models. Results: Our findings indicated that epigenetic changes played a role in immunosuppressed signalling during PDAC progression. Moreover, we identified FOSL2 as a critical regulator that was up-regulated in PDAC and associated with poor prognosis in patients. FOSL2 promoted cell proliferation, migration, and invasion. Importantly, our research revealed that FOSL2 acted as a downstream target of the KRAS/MAPK pathway and recruited regulatory T (Treg) cells by transcriptionally activating C-C motif chemokine ligand 28 (CCL28). This discovery highlighted the role of an immunosuppressed regulatory axis involving KRAS/MAPK-FOSL2-CCL28-Treg cells in the development of PDAC. Conclusion: Our study uncovered that KRAS-driven FOSL2 promoted PDAC progression by transcriptionally activating CCL28, revealing an immunosuppressive role for FOSL2 in PDAC.
- 28 June 2023
- Published by Springer Nature in British Journal of Cancer
- Vol. 129 (3) , 426-443
Open AccessChromatin accessibility uncovers KRAS-driven FOSL2 promoting pancreatic ductal adenocarcinoma progression through up-regulation of CCL28
Background: The epigenetic mechanisms involved in the progression of pancreatic ductal adenocarcinoma (PDAC) remain largely unexplored. This study aimed to identify key transcription factors (TFs) through multiomics sequencing to investigate the molecular mechanisms of TFs that play critical roles in PDAC. Methods: To characterise the epigenetic landscape of genetically engineered mouse models (GEMMs) of PDAC with or without KRAS and/or TP53 mutations, we employed ATAC-seq, H3K27ac ChIP-seq, and RNA-seq. The effect of Fos-like antigen 2 (FOSL2) on survival was assessed using the Kaplan–Meier method and multivariate Cox regression analysis for PDAC patients. To study the potential targets of FOSL2, we performed Cleavage Under Targets and Tagmentation (CUT&Tag). To explore the functions and underlying mechanisms of FOSL2 in PDAC progression, we employed several assays, including CCK8, transwell migration and invasion, RT-qPCR, Western blotting analysis, IHC, ChIP-qPCR, dual-luciferase reporter, and xenograft models. Results: Our findings indicated that epigenetic changes played a role in immunosuppressed signalling during PDAC progression. Moreover, we identified FOSL2 as a critical regulator that was up-regulated in PDAC and associated with poor prognosis in patients. FOSL2 promoted cell proliferation, migration, and invasion. Importantly, our research revealed that FOSL2 acted as a downstream target of the KRAS/MAPK pathway and recruited regulatory T (Treg) cells by transcriptionally activating C-C motif chemokine ligand 28 (CCL28). This discovery highlighted the role of an immunosuppressed regulatory axis involving KRAS/MAPK-FOSL2-CCL28-Treg cells in the development of PDAC. Conclusion: Our study uncovered that KRAS-driven FOSL2 promoted PDAC progression by transcriptionally activating CCL28, revealing an immunosuppressive role for FOSL2 in PDAC.
- Open Access
- 16 December 2021
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11, 739309
Case Report: Identification of Multiple TERT and FGFR2 Gene Fusions in a Pineal Region Glioblastoma Case
As an oncogenic somatic variant, telomerase reverse transcriptase promoter (TERTp) mutations are frequently observed in adult glioblastoma (GBM). Alternatively, we report the first case of glioblastoma with TERT amplification accompanied by multiple TERT and FGFR2 gene fusions instead of TERTp mutation. A 55-year-old woman presented with dizziness, headache, and diplopia for three weeks. Magnetic resonance imaging (MRI) demonstrated a heterogeneously enhancing lobulated mass centered in the pineal region. Partial tumor resection and ventriculoperitoneal shunt were achieved, and the residual tumor was then treated with standard radiation. The tumor was diagnosed as GBM, IDH-wild type, WHO grade IV, and the Ki67 proliferation index was high (30–40%). Intriguingly, TERT amplification without TERTp mutation was identified via next generation sequencing (NGS). Further analysis revealed multiple TERT (TERT–NUBPL, MARCH6–TERT, and CJD4–TERT) and FGFR2 (CXCL17–FGFR2, SIPA1L3–FGFR2, FGFR2–SIPA1L3, and FGFR2–CEACAM1) gene fusions. After the surgery, the patient’s condition deteriorated rapidly due to the malignant nature of the tumor and she died with an overall survival of 3 months. Our report provides the molecular clue for a novel telomerase activation and maintenance mechanism in GBM.
- 16 December 2021
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11, 739309
Open AccessCase Report: Identification of Multiple TERT and FGFR2 Gene Fusions in a Pineal Region Glioblastoma Case
As an oncogenic somatic variant, telomerase reverse transcriptase promoter (TERTp) mutations are frequently observed in adult glioblastoma (GBM). Alternatively, we report the first case of glioblastoma with TERT amplification accompanied by multiple TERT and FGFR2 gene fusions instead of TERTp mutation. A 55-year-old woman presented with dizziness, headache, and diplopia for three weeks. Magnetic resonance imaging (MRI) demonstrated a heterogeneously enhancing lobulated mass centered in the pineal region. Partial tumor resection and ventriculoperitoneal shunt were achieved, and the residual tumor was then treated with standard radiation. The tumor was diagnosed as GBM, IDH-wild type, WHO grade IV, and the Ki67 proliferation index was high (30–40%). Intriguingly, TERT amplification without TERTp mutation was identified via next generation sequencing (NGS). Further analysis revealed multiple TERT (TERT–NUBPL, MARCH6–TERT, and CJD4–TERT) and FGFR2 (CXCL17–FGFR2, SIPA1L3–FGFR2, FGFR2–SIPA1L3, and FGFR2–CEACAM1) gene fusions. After the surgery, the patient’s condition deteriorated rapidly due to the malignant nature of the tumor and she died with an overall survival of 3 months. Our report provides the molecular clue for a novel telomerase activation and maintenance mechanism in GBM.
- Open Access
- 7 October 2021
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 9
Evolving Landscape of Long Non-coding RNAs in Cerebrospinal Fluid: A Key Role From Diagnosis to Therapy in Brain Tumors
Long non-coding RNAs (lncRNAs) are a type of non-coding RNAs that act as molecular fingerprints and modulators of many pathophysiological processes, particularly in cancer. Specifically, lncRNAs can be involved in the pathogenesis and progression of brain tumors, affecting stemness/differentiation, replication, invasion, survival, DNA damage response, and chromatin dynamics. Furthermore, the aberrations in the expressions of these transcripts can promote treatment resistance, leading to tumor recurrence. The development of next-generation sequencing technologies and the creation of lncRNA-specific microarrays have boosted the study of lncRNA etiology. Cerebrospinal fluid (CSF) directly mirrors the biological fluid of biochemical processes in the brain. It can be enriched for small molecules, peptides, or proteins released by the neurons of the central nervous system (CNS) or immune cells. Therefore, strategies that identify and target CSF lncRNAs may be attractive as early diagnostic and therapeutic options. In this review, we have reviewed the studies on CSF lncRNAs in the context of brain tumor pathogenesis and progression and discuss their potential as biomarkers and therapeutic targets.
- 7 October 2021
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 9
Open AccessEvolving Landscape of Long Non-coding RNAs in Cerebrospinal Fluid: A Key Role From Diagnosis to Therapy in Brain Tumors
Long non-coding RNAs (lncRNAs) are a type of non-coding RNAs that act as molecular fingerprints and modulators of many pathophysiological processes, particularly in cancer. Specifically, lncRNAs can be involved in the pathogenesis and progression of brain tumors, affecting stemness/differentiation, replication, invasion, survival, DNA damage response, and chromatin dynamics. Furthermore, the aberrations in the expressions of these transcripts can promote treatment resistance, leading to tumor recurrence. The development of next-generation sequencing technologies and the creation of lncRNA-specific microarrays have boosted the study of lncRNA etiology. Cerebrospinal fluid (CSF) directly mirrors the biological fluid of biochemical processes in the brain. It can be enriched for small molecules, peptides, or proteins released by the neurons of the central nervous system (CNS) or immune cells. Therefore, strategies that identify and target CSF lncRNAs may be attractive as early diagnostic and therapeutic options. In this review, we have reviewed the studies on CSF lncRNAs in the context of brain tumor pathogenesis and progression and discuss their potential as biomarkers and therapeutic targets.